Israel Health News API

{
    "totalArticles": 18312,
    "articles": [
        {
            "id": "4cd454e440d44e07ba370fee4927eb06",
            "title": "טרשת נפוצה: טיפול מבטיח בתרופות ותיקות",
            "description": "שילוב של תרופה לסוכרת ואנטיהיסטמין הראה סימנים התחלתיים לשיקום עצבי אצל חולים במחלה הדלקתית הניוונית הקשה",
            "content": "מחקר חדש מצא שחולי טרשת נפוצה שקיבלו שילוב של שתי תרופות מוכרות ושכיחות שימרו טוב יותר את מהירות ההולכה העצבית בין תאי מוחם. זוהי ראיה ראשונית לקיומה של אפשרות לתיקון המיאלין – החומר המבודד שמקל על העברת שדרים עצביים במוח, ושפגיעה מתמשכת בו אחראית לי... [4289 chars]",
            "url": "https://www.mako.co.il/health-illnesses-and-medicines/Article-10f8271da416d91026.htm",
            "image": "https://img.mako.co.il/2025/07/16/shutterstock_796603354_autoOrient_w.jpg",
            "publishedAt": "2026-05-28T16:32:00Z",
            "lang": "he",
            "source": {
                "id": "70b933aab04f55b2e66f8a42d4c1e3f3",
                "name": "mako",
                "url": "https://www.mako.co.il"
            }
        },
        {
            "id": "fd4b9bfddd4e4f63f662977bd9efa7ed",
            "title": "SURPASS-CVOT: Tirzepatide Significantly Reduces Major Kidney Events Compared to Dulaglutide in T2D",
            "description": "SURPASS-CVOT shows tirzepatide cuts major kidney events vs dulaglutide in type 2 diabetes, slowing eGFR decline.",
            "content": "A study published in The Lancet Diabetes & Endocrinology found that tirzepatide, a first-in-class dual agonist targeting the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor, diminishes the risk of major kidney event... [3735 chars]",
            "url": "https://www.docwirenews.com/post/surpass-cvot-trial-shows-tirzepatide-significantly-reduces-major-kidney-events-compared-to-dulaglutide-in-type-2-diabetes",
            "image": "https://mumcdnstorage.blob.core.windows.net/dwnews/2026/05/iStock-2211882789.jpg",
            "publishedAt": "2026-05-28T16:16:00Z",
            "lang": "en",
            "source": {
                "id": "885ae2dda50884da7e0cf7fb8d4aa961",
                "name": "Docwire News",
                "url": "https://www.docwirenews.com"
            }
        },
        {
            "id": "7d4b1e34605ea8c04a4053bbdd569f62",
            "title": "Influenza Vaccine Study in Older Adults Supports Flexible Vaccine Strategies for Health Systems and Long-Term Care Facilities",
            "description": "A large real-world study involving more than 430,000 adults aged 65 years and older found comparable effectiveness between adjuvanted and high-dose influenza vaccines, reinforcing current ACIP recommendations and giving health care systems greater flexibility during vaccine procurement and influenza season planning.\nIn this Q&A, Mendel Haag, PhD, senior director of the Center of Outcomes Research & Epidemiology in global medical affairs at CSL Seqirus, discusses vaccine confidence, influenza misinformation, operational barriers to vaccination, and why ongoing real-world evidence remains critical for protecting vulnerable older adult populations.",
            "content": "Older adults remain disproportionately vulnerable to severe influenza-related complications, hospitalizations, and death, making effective vaccination strategies a major priority for infection preventionists, long-term care facilities, and health car... [7254 chars]",
            "url": "https://www.infectioncontroltoday.com/view/influenza-vaccine-study-older-adults-supports-flexible-vaccine-strategies-health-systems-long-term-care-facilities",
            "image": "https://cdn.sanity.io/images/0vv8moc6/infenctioncontrol/5c96f3c7d81c587c1af3071811c4bf568a159ffd-1920x1080.jpg",
            "publishedAt": "2026-05-28T16:15:31Z",
            "lang": "en",
            "source": {
                "id": "9b82de39e27b4272a6d9e3ad011b1f49",
                "name": "Infection Control Today",
                "url": "https://www.infectioncontroltoday.com"
            }
        }
    ]
}